NeoGenomics (NASDAQ:NEO) Given New $19.00 Price Target at Ne

NeoGenomics (NASDAQ:NEO – Get Free Report) had its target price decreased by equities research analysts at Needham & Company LLC from $24.00 to $19.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Needham & Company LLC’s price target indicates […]

Related Keywords

United Kingdom , United States , Aliciac Olivo , William Blair , Piper Sandler , Needham Company , Burkett Financial Services , Quadrant Capital Group , Clinical Services , Neogenomics Inc , Financial Services Group Inc , Neogenomics Company Profile , Goldman Sachs Group , Bluepath Capital Management , Get Free Report , General Counsel Alicia , Path Capital Management , Financial Services , Capital Group , Services Group , Advanced Diagnostics , Neogenomics Daily , Neogenomics , Nasdaq Neo , Neo , Medical , Lower Price Target , Needham Company Llc ,